Volume 7.10 | Mar 20

Immune Regulation News 7.10 March 20, 2015
Immune Regulation News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Like Us on Facebook  IRN on Twitter
Researchers Tweak the Immune System to Target Cells Bearing Tumor Antigens
Scientists have developed human T cell receptors (TCRs) that have no tolerance toward human cancer antigens and specifically recognize the antigen MAGE-A1, which is present on various human tumor cells. Instead of directly using human-derived TCRs, which do not mediate substantial anti-tumor effects, the scientists took a “detour” over a mouse model. [Press release from Max Delbrück Center for Molecular Medicine discussing online prepublication in Nature Biotechnology] Press Release | Abstract
Request a Sample: 8 minutes to highly purified immune cells with EasySep™.
PUBLICATIONS (Ranked by impact factor of the journal)
Regulatory T Cells Generated Early in Life Play a Distinct Role in Maintaining Self-Tolerance
Investigators report that Aire promotes the perinatal generation of a distinct compartment of Foxp3+CD4+ regulatory T (Treg) cells, which stably persists in adult mice. This population has a role in maintaining self-tolerance, transcriptome and activation profile distinguishable from those of Tregs produced in adults. [Science] Abstract

Network Integration of Parallel Metabolic and Transcriptional Data Reveals Metabolic Modules that Regulate Macrophage Polarization
By using an integrated high-throughput transcriptional-metabolic profiling and analysis pipeline, researchers characterized systemic changes during murine macrophage M1 and M2 polarization. [Immunity]
Abstract | Press Release

Cigarette Smoke Silences Innate Lymphoid Cell Function and Facilitates an Exacerbated Type I Interleukin-33-Dependent Response to Infection
Researchers examined the effects of smoke priming underlying the exacerbated response to viral infection in mice. Smoke decreased ST2 expression on group 2 innate lymphoid cells (ILC2s) while elevating ST2 expression on macrophages and natural killer cells, thus altering interleukin-33 responsiveness within the lung. [Immunity] Full Article

Improved Antitumor Activity of Immunotherapy with BRAF and MEK Inhibitors in BRAFV600E Melanoma
Using a mouse model of syngeneic BRAFV600E-driven melanoma, scientists tested whether addition of the MEK (MAPK [mitogen-activated protein kinase] kinase) inhibitor trametinib would enhance the antitumor activity of combined immunotherapy with the BRAF inhibitor dabrafenib. [Sci Transl Med] Abstract | Press Release

Prosurvival Bcl-2 Family Members Reveal a Distinct Apoptotic Identity between Conventional and Plasmacytoid Dendritic Cells
Researchers investigated the molecular control of cell survival of two main dendritic cell (DC) subsets: plasmacytoid DCs and conventional DCs and their dependence on individual antiapoptotic BCL-2 family members. [Proc Natl Acad Sci USA] Abstract

Macrolide Therapy Suppresses Key Features of Experimental Steroid-Sensitive and Steroid-Insensitive Asthma
Scientists used mouse models to investigate the effects of clarithromycin and amoxicillin treatment on immune responses and airways hyper-responsiveness in Ova-induced, T helper lymphocyte (Th) 2-associated steroid-sensitive allergic airways disease (AAD) and infection-induced Th1/Th17-associated steroid-insensitive neutrophilic AAD compared with dexamethasone treatment. [Thorax] Abstract

Interleukin-10-Producing CD5+ B Cells Inhibit Mast Cells during Immunoglobulin E-Mediated Allergic Responses
Researchers found that interleukin-10 (IL-10)-producing CD5+ B cells suppressed the immunoglobulin E- and antigen-mediated activation of mast cells in vitro as well as allergic responses in mice in an IL-10-dependent manner. [Sci Signal] Abstract

Distinct Modes of Antigen Presentation Promote the Formation, Differentiation, and Activity of Foxp3+ Regulatory T Cells In Vivo
Researchers showed that a self-peptide with low (but not high) stimulatory potency promotes thymic regulatory T cell (Treg) formation and can induce conventional CD4+ T cells in the periphery to become Tregs that express different levels of the transcription factor Helios according to anatomical location. [J Immunol] Abstract

Subscribe to our sister publications:
Human Immunology News and Immunology of Infectious Disease News

March Magnet Maddness: Free EasySep™ Magnet with Purchase of Cell Isolation Reagents
Control of Adaptive Immunity by the Innate Immune System
Multiple mechanisms for the induction of immune responses are variations on a common design principle wherein the cells that sense infections produce one set of cytokines to induce lymphocytes to produce another set of cytokines, which in turn activate effector responses. The authors discuss these emerging principles of innate control of adaptive immunity. [Nat Immunol] Abstract

Regulatory T Cells Turn Pathogenic
Unstable Foxp3+ regulatory T (Treg) cells play roles in the pathogenesis of diseases, which cause safety concerns regarding human Treg cell therapy. The authors highlight recent findings that demonstrate the pathogenic conversion of Treg cells in different disease models. [Cell Mol Immunol] Abstract

Visit our reviews page to see a complete list of reviews in the immune regulation research field.
Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases
Kineta, Inc. presented encouraging pre-clinical animal results using ShK-186 in a novel ocular formulation as a topical therapy for autoimmune eye disease. [Press release from Kineta, Inc. discussing research presented at the 7th Ocular Diseases Drug Discovery Conference, San Diego] Press Release | Poster

From our sponsor: Free Nature Reviews Immunology poster – Immune Response to HIV. Request a copy.
ImmunoCellular Therapeutics Establishes Manufacturing Agreement with PharmaCell B.V. for European Production of ICT-107 for Phase III Registration Trial
ImmunoCellular Therapeutics, Ltd. announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma. [ImmunoCellular Therapeutics, Ltd.] Press Release

Kite Pharma Strengthens Its T Cell Receptor (TCR) Cancer Gene Therapy Platform through Acquisition of T-Cell Factory B.V. (TCF™)
Kite Pharma, Inc. announced that it has further strengthened its TCR product platform and established a European presence through the acquisition of TCF™. TCF has the ability to discover and develop tumor-specific TCRs for broad application in cancer treatment based on its proprietary TCR-GENErator™ platform. [Kite Pharma, Inc.] Press Release

Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy
Eli Lilly and Company and Hanmi Pharmaceutical Co., Ltd. announced they have entered into an exclusive license and collaboration agreement for the development and commercialization of Hanmi’s oral Bruton’s tyrosine kinase inhibitor, HM71224, for the treatment of autoimmune and other diseases. [Eli Lilly and Company] Press Release

Intarcia and Numab Sign Multi-Asset Collaboration to Develop Once-Yearly Therapies in Diabetes, Obesity, and Autoimmune Indications
Intarcia Therapeutics, Inc. and Numab AG announced a strategic collaboration focused on the development of once- or twice-yearly mono-specific and multi-specific antibodies addressing diabetes, obesity and autoimmune indications. [Intarcia Therapeutics, Inc.] Press Release

VAXIL Receives EU Orphan Drug Designation for ImMucin for the Treatment of Multiple Myeloma
Vaxil Bio reports that its lead drug candidate, ImMucin has received orphan drug designation from the European Medicines Agency of the European Commission for the treatment of multiple myeloma. [Vaxil BioTherapeutics Ltd.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW EMBO Workshop – Cellular and Molecular Mechanism of Tumor-Microenvironment Crosstalk
July 9-12, 2015
Tomsk, Russia

NEW Gordon Research Conference – Hormone-Dependent Cancers
August 16-21, 2015
Newry, United States

NEW The 2015 Vaccine Summit
October 13-15, 2015
London, United Kingdom

Visit our events page to see a complete list of events in the immune regulation community.
NEW Senior Immunologist (Immune Targeting Systems Ltd.)

NEW Postdoctoral Position – Genome Dynamics in the Immune System (Imagine Institute)

Manufacturing Manager – Cell Therapy (Opexa Therapeutics)

Postdoctoral Research Fellow – Molecular Aspects of Autoimmunity (Singapore Immunology Network A*STAR)

PhD Studentship – Mouse Models of Asthma (University of Queensland)

Postdoctoral Researcher – Tumor Immunology and Immunotherapy (Cleveland Clinic Lerner Research Institute)

Director – Vector Production (Sangamo BioSciences, Inc.)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Assistant/Associate Professor – Gastroenterology (North Carolina State University College of Veterinary Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Immune Regulation News: Archives | Events | Contact Us